Vera Therapeutics appoints James R. Meyers to Board of Directors

Vera Therapeutics, Inc.

James R. Meyers appointed as Class II Director effective Nov 25, 2025; term expires at 2026 annual meeting.
Appointed to Audit Committee; received nonstatutory stock option for 25,000 shares vesting monthly over 3 years.
Annual cash retainer of $40k plus $10k Audit Committee retainer, pro-rated for 2025.
Eligible for annual option grant at 2026 meeting: lesser of 14,000 shares or fair value not exceeding $400,000.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.